Business UpdateAug 13, 2026, 08:32 AM
PDS Biotech Prioritizes PDS0301 After Positive Phase 2 Data
AI Summary
PDS Biotechnology announced a strategic refocus, prioritizing its PDS0301 immunocytokine as the lead development program following positive Phase 2 clinical data in metastatic colorectal cancer. The data showed a 77.8% objective response rate and an 80% 24-month survival rate. As part of this strategy, the company will cease internal investment in PDS0101 and seek partnerships for its continued development. For Q2 2026, PDS Biotech reported a net loss of $9.8 million, or $0.18 per share, with a cash balance of $5.6 million.
Key Highlights
- PDS Biotech prioritizes PDS0301 as its lead development program.
- Positive Phase 2 data for PDS0301 showed 77.8% ORR and ~80% 24-month survival rate.
- Company discontinued internal investment in PDS0101, seeking partnerships.
- Q2 2026 net loss was $9.8 million, or $0.18 per basic and diluted share.
- Research and development expenses decreased to $3.3 million in Q2 2026.
- Cash balance was $5.6 million as of June 30, 2026.
- Long-term debt was reduced to $0 as of June 30, 2026.
Price Impact
More from PDSB